Evaxion Biotech remains a high-risk, clinical-stage entity whose valuation is tethered to the success of its AI-driven PIONEER platform rather than consistent commercial performance.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and traded as low as $2.95. Evaxion A/S shares last traded at $3.08, with a volume of 219,538 shares. Analyst Ratings Changes Separately, Weiss
COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.
COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma.
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.
Benchmark EVAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Evaxion Biotech A/S (EVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.00 | $18.95M | -0.14 | 125.12% | -115.49% | -61.39% | — | |
| $0.63 | $10.51M | 1.29 | -33.66% | 397.84% | 34.15% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — | |
| $8.04 | $3.59B | -16.62 | 60.6% | -58.19% | -29.71% | — | |
| $166.89 | $207.21B | -54.05 | 2.39% | -12.47% | -21.84% | 1.91% |
Evaxion Biotech A/S (EVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Evaxion Biotech A/S (EVAX) stock FAQ — growth, dividends, profitability & financials explained
Evaxion Biotech A/S (EVAX) reported $7.5M in revenue in fiscal year 2025, which is also its trailing twelve months.
Evaxion Biotech A/S (EVAX) grew revenue by 135.9% over the trailing twelve months, compared with the twelve months before.
No. Evaxion Biotech A/S (EVAX) reported a net loss of $8.7M over the trailing twelve months.
Evaxion Biotech A/S (EVAX) had a return on equity (ROE) of -61.4% over the trailing twelve months. A negative ROE means the company lost money over the period.
